Abstract
Alzheimer’s disease is the most common form of dementia and is characterized by a progressive loss of cognitive functions. As the result of predicted demographic changes over the next decades, Alzheimer’s disease is expected to be one of the most pressing medical and social challenges facing our generation. Current treatment strategies remain symptomatic. However, new approaches have shown promise in clinical trials, particularly in patients with only mild or moderate symptoms. Early detection of Alzheimer’s disease is therefore of critical importance. Currently available diagnostic approaches (such as protein analysis in cerebrospinal fluid or neuroimaging), however, are expensive and invasive and therefore unsuitable for the screening of a large population. Consequently, Alzheimer’s disease is generally diagnosed too late for effective intervention. MicroRNAs—readily measurable in biofluids and resistant to freeze-thaw and pH changes, have shown encouraging diagnostic potential in Alzheimer’s disease. Several studies have attempted to correlate changes of specific microRNAs to disease progression using different approaches and profiling platforms including micro-arrays, RNA sequencing, and qPCR-based systems. In the present book chapter, we will describe the different steps involved in how to determine the microRNA profile in plasma samples from patients using the OpenArray platform.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer’s disease
- Ago2:
-
Argonaute-2
- APP:
-
Amyloid precursor protein
- Aβ:
-
Amyloid β
- CSF:
-
Cerebrospinal fluid
- Ct:
-
Cycle threshold
- GMN:
-
Global mean normalization
- MCI:
-
Mild cognitive impairment
- miRNA:
-
MicroRNA
- NC:
-
Normal cognition
- NFT:
-
Neurofibrillary tangles
- NTC:
-
No template controls (negative control)
- PHF:
-
Paired helical filaments
- PreAmp:
-
Pre-amplification
- qPCR:
-
Quantitative polymerase chain reaction
- RT:
-
Reverse transcription
- TE:
-
Tris + EDTA
References
Scheltens P, Blennow K, Breteler MM et al (2016) Alzheimer’s disease. Lancet 388:505–517
Di Domenico F, Tramutola A, Butterfield DA (2017) Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of Alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic Biol Med 111:253–261
Madeira C, Lourenco MV, Vargas-Lopes C et al (2015) d-Serine levels in Alzheimer’s disease: implications for novel biomarker development. Transl Psychiatry 5:e561
Yin F, Sancheti H, Liu Z et al (2016) Mitochondrial function in ageing: coordination with signalling and transcriptional pathways. J Physiol 594:2025–2042
Brooks LG, Loewenstein DA (2010) Assessing the progression of mild cognitive impairment to Alzheimer’s disease: current trends and future directions. Alzheimers Res Ther 2:28
Heister D, Brewer JB, Magda S et al (2011) Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77:1619–1628
Barnes DE, Cenzer IS, Yaffe K et al (2014) A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer’s disease. Alzheimers Dement 10:646–655
Dufouil C, Fuhrer R, Alperovitch A (2005) Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc 53:616–621
Frisardi V, Solfrizzi V, Seripa D et al (2010) Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res Rev 9:399–417
Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6:1054–1061
Gasparini L, Racchi M, Binetti G et al (1998) Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer’s disease. FASEB J 12:17–34
Joachim CL, Mori H, Selkoe DJ (1989) Amyloid beta-protein deposition in tissues other than brain in Alzheimer’s disease. Nature 341:226–230
Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362
Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
Erson AE, Petty EM (2008) MicroRNAs in development and disease. Clin Genet 74:296–306
Weber JA, Baxter DH, Zhang S et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741
de Planell-Saguer M, Rodicio MC (2011) Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 699:134–152
Pritchard CC, Cheng HH, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13:358–369
Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008
McDonald JS, Milosevic D, Reddi HV et al (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57:833–840
Kumar L, Shamsuzzama, Haque R et al (2016) Circular RNAs: the emerging class of non-coding RNAs and their potential role in human neurodegenerative diseases. Mol Neurobiol [Epub ahead of print]
Schonrock N, Matamales M, Ittner LM et al (2012) MicroRNA networks surrounding APP and amyloid-beta metabolism—implications for Alzheimer’s disease. Exp Neurol 235:447–454
Santa-Maria I, Alaniz ME, Renwick N et al (2015) Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest 125:681–686
Reddy PH, Tonk S, Kumar S et al (2017) A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer’s disease. Biochem Biophys Res Commun 483:1156–1165
Schipper HM, Maes OC, Chertkow HM et al (2007) MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 1:263–274
Satoh J, Kino Y, Niida S (2015) MicroRNA-Seq data analysis pipeline to identify blood biomarkers for Alzheimer’s disease from public data. Biomark Insights 10:21–31
Geekiyanage H, Jicha GA, Nelson PT et al (2012) Blood serum miRNA: non-invasive biomarkers for Alzheimer’s disease. Exp Neurol 235:491–496
Galimberti D, Villa C, Fenoglio C et al (2014) Circulating miRNAs as potential biomarkers in Alzheimer’s disease. J Alzheimers Dis 42:1261–1267
Tan L, Yu JT, Tan MS et al (2014) Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer’s disease. J Alzheimers Dis 40:1017–1027
Kumar P, Dezso Z, MacKenzie C et al (2013) Circulating miRNA biomarkers for Alzheimer’s disease. PLoS One 8:e69807
Riancho J, Vazquez-Higuera JL, Pozueta A et al (2017) MicroRNA profile in patients with Alzheimer’s disease: analysis of miR-9-5p and miR-598 in raw and exosome enriched cerebrospinal fluid samples. J Alzheimers Dis 57:483–491
Kumar S, Reddy PH (2016) Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta 1862:1617–1627
Pan Y, Liu R, Terpstra E et al (2016) Dysregulation and diagnostic potential of microRNA in Alzheimer’s disease. J Alzheimers Dis 49:1–12
Hu YB, Li CB, Song N et al (2016) Diagnostic value of microRNA for Alzheimer’s disease: a systematic review and meta-analysis. Front Aging Neurosci 8:13
Mestdagh P, Van Vlierberghe P, De Weer A et al (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64
Acknowledgments
This work was supported by funding from Science Foundation Ireland (13/SIRG/2114 to E.M.J.-M. and 12/COEN/18 and 13/SIRG/2098 to T.E.), from the Health Research Board Ireland (HRA-POR-2015-1243 to T.E.), and from Carlos III Institute of Health (SAF2016-78603-R to M.M. and M.C.).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kenny, A., Jimenez-Mateos, E.M., Calero, M., Medina, M., Engel, T. (2018). Detecting Circulating MicroRNAs as Biomarkers in Alzheimer’s Disease. In: Sigurdsson, E., Calero, M., Gasset, M. (eds) Amyloid Proteins. Methods in Molecular Biology, vol 1779. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7816-8_29
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7816-8_29
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7815-1
Online ISBN: 978-1-4939-7816-8
eBook Packages: Springer Protocols